PTC Therapeutics, Inc.(PTCT)Earnings, Financials & Key RatiosPTC Therapeutics, Inc. (PTCT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's core operations are currently unable to sustain its $100.9 million quarterly R&D intensity without relying on non-recurring asset sales, which have already caused cash reserves to decline from $1.5 billion in 2025Q1 to $834.0 million in 2026Q1.
PTC Therapeutics, Inc. (PTCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
PTC Therapeutics, Inc. (PTCT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.03vs $0.45+93.3% | $273Mvs $217M+25.4% |
| Q1 2026 | Feb 19, 2026 | $1.67vs $0.21-695.2% | $165Mvs $279M-41.1% |
| Q4 2025 | Nov 4, 2025 | $0.20vs $1.19+116.8% | $211Mvs $281M-25.0% |
| Q3 2025 | Aug 7, 2025 | $0.83vs $1.07+22.4% | $179Mvs $191M-6.6% |
Recent stock market news and headlines for PTC Therapeutics, Inc. (PTCT)
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – – Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Key metrics vs top competitors for PTC Therapeutics, Inc. (PTCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $85.44 | $7.09B | 10.98 | 114.51% | 39.44% | — | — | |
| $19.18 | $2.02B | -2.69 | 15.58% | 2.98% | 4.89% | — | |
| $58.79 | $11.31B | 32.66 | 12.87% | 8.29% | 4.41% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $313.04 | $41.77B | 134.35 | 65.19% | 13.46% | 98.29% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — |
PTC Therapeutics, Inc. (PTCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTC Therapeutics, Inc. (PTCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 28, 2026·SEC
Mar 25, 2026·SEC
Get notified when PTCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTC Therapeutics, Inc. (PTCT) stock FAQ — growth, dividends, profitability & financials explained
PTC Therapeutics, Inc. (PTCT) reported $827.1M in revenue for fiscal year 2025. This represents a 736% increase from $99.0M in 2011.
PTC Therapeutics, Inc. (PTCT) grew revenue by 114.5% over the past year. This is strong growth.
PTC Therapeutics, Inc. (PTCT) reported a net loss of $186.7M for fiscal year 2025.
PTC Therapeutics, Inc. (PTCT) had negative free cash flow of $229.0M in fiscal year 2025, likely due to heavy capital investments.
